Shanghai INT Medical Instruments Co Rule of 40
The Rule of 40 of Shanghai INT Medical Instruments Co (1501.HK) as of Oct 11, 2026 is 71.11 %. In the previous year, Rule of 40 was 38.54 % — a change of 84.50% (higher).
Get this data via API
Financial Data API
Rule of 40
71.11 %
YoY
84.50%
Last updated:
Rule of 40 of Shanghai INT Medical Instruments Co is 2025 71.11 % . Rule of 40 of Shanghai INT Medical Instruments Co was 2024 38.54 % . It decreases by 84.50% higher compared to the previous year.
The Shanghai INT Medical Instruments Co Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
81.11 CNY
Jan 1, 2019
80.78 CNY
Jan 1, 2020
63.40 CNY
Jan 1, 2021
84.61 CNY
Jan 1, 2022
50.88 CNY
Jan 1, 2023
34.03 CNY
Jan 1, 2024
38.54 CNY
Jan 1, 2025
71.11 CNY
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 71.11 % | +84.50% | |
| 38.54 % | +13.26% | |
| 34.03 % | -33.12% | |
| 50.88 % | -39.86% | |
| 84.61 % | +33.46% | |
| 63.40 % | -21.52% | |
| 80.78 % | -0.41% | |
| 81.11 % | +26.89% | |
| 63.92 % | — |
Access this data via the Eulerpool API
Shanghai INT Medical Instruments Co Stock analysis
What does Shanghai INT Medical Instruments Co do? Shanghai INT Medical Instruments Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Shanghai INT Medical Instruments Co stock
Rule of 40 of Shanghai INT Medical Instruments Co is 71.11 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Shanghai INT Medical Instruments Co since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
Quality — Shanghai INT Medical Instruments Co
All Key Metrics — Shanghai INT Medical Instruments Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth